High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
A veteran in cell therapy and oncology commercialisation
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Subscribe To Our Newsletter & Stay Updated
